The tumor suppressing role of USP33 is at least partially dependent on β-arrestin-mediated ERK signaling downstream of SDF-1/CXCR4, demonstrating the prospect of deubiquitinating enzyme modulator and biased-ligand development of GPCRs in cancer therapy. This evidence concerns the gene CXCR4 and neoplasm.